The safety and efficacy of durvalumab consolidation therapy in the management of patients with stage III non-small-cell lung cancer and preexisting interstitial lung disease
Copyright © 2022 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved..
BACKGROUND: Some lung cancer patients have preexisting interstitial lung disease (ILD), which is considered a risk factor for lung cancer treatment. This study investigated the safety and efficacy of durvalumab consolidation therapy for patients with stage III non-small-cell lung cancer (NSCLC) and preexisting ILD.
METHODS: Fifty consecutive patients who were judged to be tolerable to concurrent chemoradiotherapy (CCRT) for stage III NSCLC were enrolled. Differences in the incidence rate of radiation pneumonitis (RP) and progression-free survival (PFS) were assessed in patients with or without ILD of which CT showed non-usual interstitial pneumonia pattern between the durvalumab consolidation group and chemotherapy (combination of carboplatin and paclitaxel [CP]) consolidation group.
RESULTS: The incidence of RP was higher in patients with preexisting ILD (40% and 20% in the durvalumab and CP groups, respectively) than in those without ILD (26% and 8% in the durvalumab and CP groups, respectively). Univariate analysis showed that durvalumab therapy tended to increase the incidence of RP; however, preexisting ILD did not significantly increase the incidence of RP. The condition of all patients who developed RP improved with the administration of oral prednisolone. Among patients without ILD, the median PFS was 17 and 16 months in the durvalumab and CP groups, respectively. Among patients with preexisting ILD, median PFS was not achieved in the durvalumab group and was 8 months in the CP group.
CONCLUSIONS: Although durvalumab consolidation therapy tended to increase the incidence of RP, it might be tolerable in stage III NSCLC patients with preexisting ILD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:60 |
|---|---|
| Enthalten in: |
Respiratory investigation - 60(2022), 5 vom: 20. Sept., Seite 667-673 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kawanaka, Yusuke [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
28X28X9OKV |
|---|
| Anmerkungen: |
Date Completed 18.08.2022 Date Revised 18.08.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.resinv.2022.05.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342469525 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342469525 | ||
| 003 | DE-627 | ||
| 005 | 20231226014203.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.resinv.2022.05.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1141.xml |
| 035 | |a (DE-627)NLM342469525 | ||
| 035 | |a (NLM)35725721 | ||
| 035 | |a (PII)S2212-5345(22)00059-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kawanaka, Yusuke |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The safety and efficacy of durvalumab consolidation therapy in the management of patients with stage III non-small-cell lung cancer and preexisting interstitial lung disease |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.08.2022 | ||
| 500 | |a Date Revised 18.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: Some lung cancer patients have preexisting interstitial lung disease (ILD), which is considered a risk factor for lung cancer treatment. This study investigated the safety and efficacy of durvalumab consolidation therapy for patients with stage III non-small-cell lung cancer (NSCLC) and preexisting ILD | ||
| 520 | |a METHODS: Fifty consecutive patients who were judged to be tolerable to concurrent chemoradiotherapy (CCRT) for stage III NSCLC were enrolled. Differences in the incidence rate of radiation pneumonitis (RP) and progression-free survival (PFS) were assessed in patients with or without ILD of which CT showed non-usual interstitial pneumonia pattern between the durvalumab consolidation group and chemotherapy (combination of carboplatin and paclitaxel [CP]) consolidation group | ||
| 520 | |a RESULTS: The incidence of RP was higher in patients with preexisting ILD (40% and 20% in the durvalumab and CP groups, respectively) than in those without ILD (26% and 8% in the durvalumab and CP groups, respectively). Univariate analysis showed that durvalumab therapy tended to increase the incidence of RP; however, preexisting ILD did not significantly increase the incidence of RP. The condition of all patients who developed RP improved with the administration of oral prednisolone. Among patients without ILD, the median PFS was 17 and 16 months in the durvalumab and CP groups, respectively. Among patients with preexisting ILD, median PFS was not achieved in the durvalumab group and was 8 months in the CP group | ||
| 520 | |a CONCLUSIONS: Although durvalumab consolidation therapy tended to increase the incidence of RP, it might be tolerable in stage III NSCLC patients with preexisting ILD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Durvalumab | |
| 650 | 4 | |a Interstitial lung disease | |
| 650 | 4 | |a Non-small-cell lung cancer | |
| 650 | 4 | |a Radiation pneumonitis | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a durvalumab |2 NLM | |
| 650 | 7 | |a 28X28X9OKV |2 NLM | |
| 650 | 7 | |a Carboplatin |2 NLM | |
| 650 | 7 | |a BG3F62OND5 |2 NLM | |
| 700 | 1 | |a Yasuda, Yuto |e verfasserin |4 aut | |
| 700 | 1 | |a Tanizaki, Junko |e verfasserin |4 aut | |
| 700 | 1 | |a Iwashima, Daisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Nonagase, Yoshikane |e verfasserin |4 aut | |
| 700 | 1 | |a Uemasu, Kiyoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Hirayama, Yutaka |e verfasserin |4 aut | |
| 700 | 1 | |a Ogura, Masakazu |e verfasserin |4 aut | |
| 700 | 1 | |a Ozaki, Tomohiro |e verfasserin |4 aut | |
| 700 | 1 | |a Takahashi, Ken-Ichi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Respiratory investigation |d 2012 |g 60(2022), 5 vom: 20. Sept., Seite 667-673 |w (DE-627)NLM217493343 |x 2212-5353 |7 nnns |
| 773 | 1 | 8 | |g volume:60 |g year:2022 |g number:5 |g day:20 |g month:09 |g pages:667-673 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.resinv.2022.05.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 60 |j 2022 |e 5 |b 20 |c 09 |h 667-673 | ||